Bausch + Lomb Corporation (BLCO)
| Market Cap | 5.63B |
| Revenue (ttm) | 5.10B |
| Net Income (ttm) | -360.00M |
| Shares Out | 356.38M |
| EPS (ttm) | -1.02 |
| PE Ratio | n/a |
| Forward PE | 20.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 483,050 |
| Open | 15.84 |
| Previous Close | 15.88 |
| Day's Range | 15.68 - 16.00 |
| 52-Week Range | 10.45 - 18.92 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 18.45 (+16.85%) |
| Earnings Date | Apr 29, 2026 |
About BLCO
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during heali... [Read more]
Financial Performance
In 2025, Bausch + Lomb's revenue was $5.10 billion, an increase of 6.47% compared to the previous year's $4.79 billion. Losses were -$360.00 million, 13.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for BLCO stock is "Buy." The 12-month stock price target is $18.45, which is an increase of 16.85% from the latest price.
News
Bausch + Lomb Releases 2025 Sustainability Impact Report
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the release of...
Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-k...
Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentati...
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter...
Bausch + Lomb Transcript: Status update
BL 1107, a novel neuroprotective glaucoma therapy, is advancing through phase II with promising early data and strong patent protection, while ELIOS, an implant-free excimer laser MIGS, has shown durable IOP reduction and medication-free rates in pivotal studies. Both assets target significant unmet needs and are expected to drive substantial growth, with ELIOS approval anticipated in 2026.
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-mo...
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation, (“BLCO" or the "Company") (NYSE:BLCO) investors that the firm has initiated an investigation int...
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first even...
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmo...
Bausch + Lomb Earnings Call Transcript: Q4 2025
Record Q4 and full year results featured 7% revenue and 27% adjusted EBITDA growth, with all segments contributing and strong operating leverage. 2026 guidance calls for 5–7% revenue growth and 15% adjusted EBITDA growth, supported by robust product launches, margin expansion, and continued execution.
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-qua...
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte...
Bausch + Lomb Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a robust innovation-driven strategy, with major product launches in consumer, contact lens, pharma, and surgical segments expected through 2029. Margin expansion, double-digit EPS growth, and strong free cash flow are forecast, supported by operational excellence and disciplined capital allocation.
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual ...
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live bet...
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman ...
Bausch + Lomb Announces Two Board of Directors Appointments
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C...
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live bet...
Bausch + Lomb Transcript: Citi Annual Global Healthcare Conference 2025
Management outlined a multi-year transformation focused on operational, financial, and innovation excellence, with Vision 27 driving margin and sales growth. Key product launches and a robust pipeline support a 5%-7% revenue CAGR and 600 basis point margin improvement by 2028.
Bausch + Lomb to Participate in Citi Global Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman ...
Bausch + Lomb Transcript: Investor Day 2025
Management outlined a strategy for 5%-7% annual revenue growth and a 23% EBITDA margin by 2028, driven by premium product launches, operational efficiencies, and a robust R&D pipeline. Key innovations include a bioactive contact lens, dual-action dry eye therapy, and precision medicine in retina, with regular launches planned through 2032.
Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-k...
Bausch + Lomb Earnings Call Transcript: Q3 2025
Q3 2025 saw 6% revenue growth, strong performance across all segments, and robust cash flow. Premium IOLs and pharmaceuticals, especially MIEBO, drove results, while margin expansion and disciplined capital allocation remain priorities.
Bausch + Lomb Announces Third-Quarter 2025 Results
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quar...
Activist Jana Takes Stake in Cooper, a Maker of Medical Devices
Bausch + Lomb is seen as a potential buyer for the contact-lens unit and the CEO said he would be interested.